Endothelin-1 and Nitric Oxide in Patients on Chronic Hemodialysis

REFERENCES

• de Leeuw PW. Patophysiology of hypertension in patients in renal replacement therapy. Blood Purif. 1994; 12: 245–251
   PubMedGoogle Scholar
• Davies DL, Schalekamp MA, Beevers DG, et al. Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet. 1973; 1: 683–686
   PubMed Web of Science ®Google Scholar
• Campigano JL, Ramirez-Muzo O, Ramirez-Gonzales R. Normal renin uremic hypertension: Study of cardiac hemodynamics, plasma volume, extracellular fluid volume, and the renin- angiotensin system. Arch Intern Med. 1976; 136: 17–23
   PubMedGoogle Scholar
• Tuckman J, Benninger JL, Reubi F. Hemodynamics and blood volume studies in long-term haemodialysis patients and in patients with successfully transplanted kidneys. Clin Sci Mod Med. 1973; 45: 155–157
   Google Scholar
• Pollock D. Renal endothelin in hypertension. Curr Opin Nephrol Hypertension. 2000; 9: 157–164
   PubMedGoogle Scholar
• Stjerniguist M. Endothelins—vasoactive peptides and growth factors. Cell Tissue. 1998; 292: 1–9
   Google Scholar
• Rossi GP, Seccia TM, Albertin G, Pessina C. Mesaurment of endothelin: Clinical and research use. Ann Clin Biochem. 2000; 37: 608–626
   PubMed Web of Science ®Google Scholar
• Benatti L, Fabbrini MS, Patrono C. Regulation of endothelin-1 biosynthesis. Ann NY Acad Sci. 1994; 714: 109–121
   PubMedGoogle Scholar
• Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF. Characteraziation of a coronary vasoconstrictor peptide produced by cultured endothelial cells. Am J Physiol. 1985; 248: 550–556
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1998; 332: 411–415
   Web of Science ®Google Scholar
• Shiffrin EL. Endothelin in hypertension. Curr Op Cardiol. 1995; 10: 485–494
   PubMedGoogle Scholar
• Simonson MS, Dunn MJ. Renal actions of endothelin peptides. Curr Opin Nephrol Hypertens. 1993; 2: 51–60
   PubMedGoogle Scholar
• Bloom IZ, Bentlen FR, Wilson MA, et al. In vivo effects of endothelin on the renal microcirculation. J Surg Res. 1993; 54: 274–280
   PubMedGoogle Scholar
• Rabelnik TJ, Kaasjager KAH, Boer P, et al. Effects of endothelin 1 on renal function in humans. Implications for physiology and patophysiology. Kidney Int. 1994; 46: 376–381
   PubMedGoogle Scholar
• Mongensen CE, Keeane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995; 346: 1080–1084
   PubMedGoogle Scholar
• Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60: 1077–1082
   PubMed Web of Science ®Google Scholar
• Rodrigez-Manas L, Lopez-Doriga P, Petider R, et al. Effect of glycemic control on the vascular nitric oxide system in patients with type 1 diabetes. J Hypertension. 2003; 21: 1137–1143
   PubMedGoogle Scholar
• Williams SB, Cusco JA, Roddy M-A, Johnstone MT, Creager MA. Impaired nitric oxide- mediated vasodilatation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 1996; 27: 567–574
   PubMed Web of Science ®Google Scholar
• Reyes AA, Karl IE, Klahr S. Role of arginine in health and in renal disease. Am J Physiol. 1994; 267: 331–346
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Acumulation of an endogenus inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339: 572–575
   PubMed Web of Science ®Google Scholar
• Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261–1266
   PubMed Web of Science ®Google Scholar
• Hand MF, Haynes WG, Webb DJ. Hemodialysis and L arginin but not D arginin correct renal faliure associated endothelial dysfunction. Kidney Int. 1998; 53: 1068–1077
   PubMed Web of Science ®Google Scholar
• Kari JA, Donald AE, Vallance DT, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997; 52: 468–472
   PubMed Web of Science ®Google Scholar
• Morris ST, McMurray J, Rodger R, Jardine AG. Impaired endothelinum-dependent vazodilatation in uremia. Nephron Dial Transplant. 2000; 15: 572–575
   Google Scholar
• Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575
   PubMed Web of Science ®Google Scholar
• Madore F, Prudhomme L, Austin JS, et al. Impact nitric oxide in blood pressure in hemodialysis patients. Am Kidney Dis. 1997; 30: 665–671
   PubMedGoogle Scholar
• Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997; 1578–1584
   PubMedGoogle Scholar
• Bussemaker E, Passauer J, Reimann D, Schulze B, Reichel W, Gross P. The vascular endothelin system is not overactive in normotensive hemodialysis patients. Kidney Int. 2002; 62: 940–948
   PubMedGoogle Scholar
• Nims RW, Darbyshire JF, Saavedra JE, et al. Colorimetric methods for the determination of nitric oxide concentration in natural aqueous solutions. Methods 1995; 7: 48–54
   Google Scholar
• Raj DSC, Vincent B, Simpson K, et al. Hemodynamic changes during hemodylisis: Role of nitric oxide and endothelin. Kidney Int. 2002; 61: 697–704
   PubMed Web of Science ®Google Scholar
• Goddard J, Johnston NR, Hand MF, et al. Endothelin-a receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation. 2004; 109: 1186–1193
   PubMed Web of Science ®Google Scholar
• Ottosson-Seeberger A, Alhorbg G, Hemsen A, et al. Hemodialysis effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol. 1999; 10: 1037–1044
   PubMedGoogle Scholar
• Hand MF, Haynes WG, Webb DJ. Reduced endogenous endothelin-1 mediated vascular tone in chronic renal failure. Kidney Int. 1999; 55: 613–620
   PubMedGoogle Scholar
• Demuth K, Blacher J, Guerin AP, et al. Endothelin and cardiovascular remodelling in end- stage renal disease. Nephrol Dial Transplant. 1998; 13: 375–383
   PubMed Web of Science ®Google Scholar
• Nabokov AV, Smann K, Wessels A, et al. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 1999; 55: 512–519
   PubMedGoogle Scholar
• Morris ST, McMurray JJ, Rodger R, Jardine AG. Impaired endothelium-dependent vasodilatationem in uremia. Nephrol Dial Transplant 2000; 15: 572–575
   Google Scholar
• Ross R. The patogenesis of atherosclerosis. A perspective for the 1990. Nature. 1993; 362: 801–809
   PubMed Web of Science ®Google Scholar
• Haynes WG, Hand MF, Dockrell MEC, et al. Physioogical role of nitric oxide in regulation of renal function in humans. Am J Physiol. 1997; 272: 364–371
   PubMed Web of Science ®Google Scholar
• Blum M, Yachnin T, Wollman Y, et al. Low nitric oxide production in patients with chronic renal failure. Nephron. 1998; 79: 265–268
   PubMed Web of Science ®Google Scholar
• Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Phisiol Renal Phisiol 1999; 276: 794–797
   PubMed Web of Science ®Google Scholar
• Vallance PA, Leone A, Calver J, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575
   PubMed Web of Science ®Google Scholar
• Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant. 2001; 16: 60–62
   PubMed Web of Science ®Google Scholar
• Ashab I, Peer G, Blum M, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995; 47: 1515–1521
   PubMed Web of Science ®Google Scholar
• Aiello S, Noris M, Todeschini M, et al. Renal and systematic nitric ocxide synthesis in rats with renal mass reduction. Kidney Int. 1997; 52: 171–181
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Ni Z, Wang XQ, Ovejsi F, Zhou XI. Downregulation of nitric oxide synthesis in chronic renal insufficiency: Role of excess PTH. Am J Physiol. 1998; 274: 642–649
   Google Scholar
• Kovac T, Barta J, Kossis B, Nagy J. Nitric oxide in IgA nephropathy patients with or without hypertension. Exp Nephrol. 1005; 3: 369–372
   Google Scholar
• Schmidt RJ, Domico J, Samsel LJ, et al. Indices of activity of the nitric oxide system in patients on hemodialysis. Am J Kidney 1999; 34: 228–234
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimetylarginine plasma concentration differ in patients with end stage renal disease: Relationship to treatment method and atherosclerosis disease. J Am Soc Nephrol. 1999; 10: 594–600
   PubMed Web of Science ®Google Scholar